ORGANOGENESIS HOLDINGS INC. Deferred Foreign Income Tax Expense (Benefit)
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Deferred Foreign Income Tax Expense (Benefit) of $27.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. deferred foreign income tax expense (benefit) for fiscal 2024 was $27.00K, a 107.69% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. deferred foreign income tax expense (benefit) for fiscal 2023 was $13.00K.
- ORGANOGENESIS HOLDINGS INC. deferred foreign income tax expense (benefit) for fiscal 2020 was $3.00K, a 50.00% decline from fiscal 2019.
- ORGANOGENESIS HOLDINGS INC. deferred foreign income tax expense (benefit) for fiscal 2019 was $6.00K.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2024-12-31 | $27.00K 10-K · filed 2026-02-26 |
| 2023-12-31 | $13.00K 10-K · filed 2026-02-26 |
| 2020-12-31 | $3.00K 10-K · filed 2023-03-01 |
| 2019-12-31 | $6.00K 10-K · filed 2022-03-01 |
| 2018-12-31 | -$26.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |